Agenus (NASDAQ:AGEN) Trading Down 8.1%

Agenus Inc (NASDAQ:AGEN)’s stock price was down 8.1% on Monday . The stock traded as low as $2.14 and last traded at $2.17, approximately 1,143,193 shares were traded during trading. A decline of 10% from the average daily volume of 1,274,203 shares. The stock had previously closed at $2.36.

Several analysts recently commented on AGEN shares. BidaskClub downgraded shares of Agenus from a “sell” rating to a “strong sell” rating in a research report on Friday, July 26th. B. Riley started coverage on shares of Agenus in a research report on Monday, April 22nd. They issued a “buy” rating and a $5.00 price target for the company.

The stock’s 50-day simple moving average is $2.67. The firm has a market cap of $316.85 million, a PE ratio of -1.51 and a beta of 1.87.

Agenus (NASDAQ:AGEN) last released its quarterly earnings results on Thursday, May 9th. The biotechnology company reported $0.12 EPS for the quarter, beating the consensus estimate of ($0.30) by $0.42. The business had revenue of $8.61 million during the quarter, compared to analysts’ expectations of $9.03 million. Analysts forecast that Agenus Inc will post -0.91 EPS for the current fiscal year.

A number of hedge funds have recently added to or reduced their stakes in AGEN. Amalgamated Bank purchased a new stake in Agenus in the 4th quarter valued at $30,000. Legal & General Group Plc increased its stake in Agenus by 47.7% in the 4th quarter. Legal & General Group Plc now owns 21,674 shares of the biotechnology company’s stock valued at $52,000 after buying an additional 7,002 shares during the period. BNP Paribas Arbitrage SA increased its stake in Agenus by 80,579.2% in the 1st quarter. BNP Paribas Arbitrage SA now owns 19,363 shares of the biotechnology company’s stock valued at $58,000 after buying an additional 19,339 shares during the period. Metropolitan Life Insurance Co. NY acquired a new position in Agenus in the 4th quarter valued at $80,000. Finally, Jane Street Group LLC acquired a new position in Agenus in the 4th quarter valued at $97,000. Hedge funds and other institutional investors own 33.20% of the company’s stock.

About Agenus (NASDAQ:AGEN)

Agenus Inc, a clinical-stage immuno-oncology company, focuses on the discovery and development of therapies that engage the body's immune system to fight cancer. The company offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; SECANT yeast display, an antibody discovery platform used for the generation of novel monoclonal antibodies; and phage display technologies.

Read More: What is a Call Option?

Receive News & Ratings for Agenus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus and related companies with MarketBeat.com's FREE daily email newsletter.